(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.85%.
Celldex Therapeutics's earnings in 2026 is -$300,549,000.On average, 16 Wall Street analysts forecast CLDX's earnings for 2026 to be -$348,655,416, with the lowest CLDX earnings forecast at -$351,702,362, and the highest CLDX earnings forecast at -$325,701,234. On average, 16 Wall Street analysts forecast CLDX's earnings for 2027 to be -$347,406,797, with the lowest CLDX earnings forecast at -$420,195,820, and the highest CLDX earnings forecast at -$305,087,232.
In 2028, CLDX is forecast to generate -$257,922,395 in earnings, with the lowest earnings forecast at -$400,956,084 and the highest earnings forecast at -$108,017,371.